InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder

Oct 4, 2021 | Anti-METH antibody, IXT-m200, General News, Grants

Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...

InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose

Sep 21, 2021 | Anti-METH antibody, IXT-m200, General News

LITTLE ROCK, AR, USA, September 20, 2021 – InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in Meth-OD, a Phase 2 study of the first-in-class anti-methamphetamine antibody IXT-m200 in...

InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder

Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News

IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...

InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose

Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants

“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...

InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

May 5, 2020 | Anti-METH antibody, IXT-m200, Grants

Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...

Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)

Feb 6, 2020 | Anti-METH antibody, IXT-m200

Source: Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...

Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)

Feb 6, 2020 | Anti-METH antibody, IXT-m200

Source: Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...

As Deaths Rise, The Urgent Search For Medications To Treat Meth | CommonHealth

Feb 5, 2020 | Anti-METH antibody, IXT-m200, METH in the news

She [Nora Volkow] lays out the range of research for drugs to treat both the acute, overdose episodes and chronic treatment. To prevent an overdose, she says the U.S. government is funding trials of a drug that could be injected into someone dangerously high on meth....

A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times

Jan 23, 2020 | METH in the news

Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times

US addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence

Jan 23, 2020 | METH in the news

Source: US addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence